# Francesca Perut

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 44 papers | 5,528 citations | 25 h-index | 51 g-index |
| 51 ext. papers | 7,629 ext. citations | 5.5 avg, IF | 4.6 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 44 | The Release of Inflammatory Mediators from Acid-Stimulated Mesenchymal Stromal Cells Favours Tumour Invasiveness and Metastasis in Osteosarcoma. *Cancers*, **2021**, 13, | 6.6 | 3 |
| 43 | Strawberry-Derived Exosome-Like Nanoparticles Prevent Oxidative Stress in Human Mesenchymal Stromal Cells. *Biomolecules*, **2021**, 11, | 5.9 | 35 |
| 42 | Sarcoma treatment in the era of molecular medicine. *EMBO Molecular Medicine*, **2020**, 12, e11131 | 12 | 48 |
| 41 | Exosomes Are Comparable to Source Adipose Stem Cells in Fat Graft Retention with Up-Regulating Early Inflammation and Angiogenesis. *Plastic and Reconstructive Surgery*, **2020**, 146, 232e | 2.7 | 3 |
| 40 | Extracellular Nanovesicles Secreted by Human Osteosarcoma Cells Promote Angiogenesis. *Cancers*, **2019**, 11, | 6.6 | 15 |
| 39 | Pre-clinical Models for Studying the Interaction Between Mesenchymal Stromal Cells and Cancer Cells and the Induction of Stemness. *Frontiers in Oncology*, **2019**, 9, 305 | 5.3 | 10 |
| 38 | Diketocarboxylic Acids and Their Esters Act as Carbonic Anhydrase IX and XII Selective Inhibitors. *ACS Medicinal Chemistry Letters*, **2019**, 10, 661-665 | 4.3 | 12 |
| 37 | The Emerging Roles of Extracellular Vesicles in Osteosarcoma. *Frontiers in Oncology*, **2019**, 9, 1342 | 5.3 | 20 |
| 36 | Spheroid-based 3D cell cultures identify salinomycin as a promising drug for the treatment of chondrosarcoma. *Journal of Orthopaedic Research*, **2018**, 36, 2305 | 3.8 | 15 |
| 35 | Exosome-like Nanovesicles Isolated from Citrus limon L. Exert Antioxidative Effect. *Current Pharmaceutical Biotechnology*, **2018**, 19, 877-885 | 2.6 | 27 |
| 34 | Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *Journal of Extracellular Vesicles*, **2018**, 7, 1535750 | 16.4 | 3642 |
| 33 | The effect of extracellular acidosis on the behaviour of mesenchymal stem cells in vitro. *European Cells and Materials*, **2017**, 33, 252-267 | 4.3 | 23 |
| 32 | Cell-based Assay System for Predicting Bone Regeneration in Patient Affected by Aseptic Nonunion and Treated with Platelet Rich Fibrin. *Current Pharmaceutical Biotechnology*, **2016**, 17, 1079-1088 | 2.6 | 3 |
| 31 | Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance. *Oncotarget*, **2016**, 7, 63408-63423 | 3.3 | 67 |
| 30 | Multimodal transfer of MDR by exosomes in human osteosarcoma. *International Journal of Oncology*, **2016**, 49, 189-96 | 4.4 | 77 |
| 29 | The Role of Autophagy in the Maintenance of Stemness and Differentiation of Mesenchymal Stem Cells. *Stem Cell Reviews and Reports*, **2016**, 12, 621-633 | 6.4 | 77 |
| 28 | Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment. *Expert Opinion on Therapeutic Targets*, **2015**, 19, 1593-605 | 6.4 | 23 |

| | | | |
|---|---|---|---|
| 27 | Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. *Stem Cell Research and Therapy*, **2015**, 6, 127 | 8.3 | 430 |
| 26 | V-ATPase as an effective therapeutic target for sarcomas. *Experimental Cell Research*, **2014**, 320, 21-32 | 4.2 | 40 |
| 25 | Exosomes: novel effectors of human platelet lysate activity. *European Cells and Materials*, **2014**, 28, 137-51; discussion 151 | 4.3 | 80 |
| 24 | V-ATPase as an effective therapeutic target for sarcomas. *Experimental Cell Research*, **2014**, 320, 21-32 | 4.2 | 28 |
| 23 | Preparation method and growth factor content of platelet concentrate influence the osteogenic differentiation of bone marrow stromal cells. *Cytotherapy*, **2013**, 15, 830-9 | 4.8 | 47 |
| 22 | Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patientsV bed. *Journal of Translational Medicine*, **2013**, 11, 268 | 8.5 | 87 |
| 21 | V-ATPase is a candidate therapeutic target for Ewing sarcoma. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2013**, 1832, 1105-16 | 6.9 | 53 |
| 20 | Insulin receptor isoforms are differently expressed during human osteoblastogenesis. *Differentiation*, **2012**, 83, 242-8 | 3.5 | 23 |
| 19 | Osteoblasts from a mandibuloacral dysplasia patient induce human blood precursors to differentiate into active osteoclasts. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2011** , 1812, 711-8 | 6.9 | 23 |
| 18 | In vitro models for the evaluation of angiogenic potential in bone engineering. *Acta Pharmacologica Sinica*, **2011**, 32, 21-30 | 8 | 27 |
| 17 | Novel soybean/gelatine-based bioactive and injectable hydroxyapatite foam: material properties and cell response. *Acta Biomaterialia*, **2011**, 7, 1780-7 | 10.8 | 31 |
| 16 | Flexible polymeric ultrathin film for mesenchymal stem cell differentiation. *Acta Biomaterialia*, **2011**, 7, 2883-91 | 10.8 | 26 |
| 15 | Background and rationale of platelet gel in orthopaedic surgery. *Musculoskeletal Surgery*, **2010**, 94, 1-8 | 2.4 | 13 |
| 14 | Apatite formation on bioactive calcium-silicate cements for dentistry affects surface topography and human marrow stromal cells proliferation. *Dental Materials*, **2010**, 26, 974-92 | 5.7 | 145 |
| 13 | Recent highlights on bone stem cells: a report from Bone Stem Cells 2009, and not only *Journal of Cellular and Molecular Medicine*, **2010**, 14, 2614-21 | 5.6 | 5 |
| 12 | Chapter 11:Mesenchymal Osteogenic Precursors for Bone Repair and Regeneration **2010**, 235-247 | | |
| 11 | Endothelial cells incubated with platelet-rich plasma express PDGF-B and ICAM-1 and induce bone marrow stromal cell migration. *Journal of Orthopaedic Research*, **2009**, 27, 1493-8 | 3.8 | 29 |
| 10 | In vitro evaluation of freeze-dried bone allografts combined with platelet rich plasma and human bone marrow stromal cells for tissue engineering. *Journal of Materials Science: Materials in Medicine* , **2009**, 20, 45-50 | 4.5 | 30 |

| | | | |
|---|---|---|---|
| 9 | Immunogenic properties of renal cell carcinoma and the pathogenesis of osteolytic bone metastases **2009**, | | 3 |
| 8 | Immunogenic properties of renal cell carcinoma and the pathogenesis of osteolytic bone metastases. *International Journal of Oncology*, **2009**, 34, 1387-93 | 1 | 10 |
| 7 | New Portland cement-based materials for endodontics mixed with articaine solution: a study of cellular response. *Journal of Endodontics*, **2008**, 34, 39-44 | 4.7 | 64 |
| 6 | Isolation, characterisation and osteogenic potential of human bone marrow stromal cells derived from the medullary cavity of the femur. *La Chirurgia Degli Organi Di Movimento*, **2008**, 92, 97-103 | | 16 |
| 5 | Innovative silicate-based cements for endodontics: a study of osteoblast-like cell response. *Journal of Biomedical Materials Research - Part A*, **2008**, 87, 477-86 | 5.4 | 51 |
| 4 | Increased osteoclast activity is associated with aggressiveness of osteosarcoma. *International Journal of Oncology*, **2008**, 33, 1231-8 | 1 | 39 |
| 3 | Improved osteogenic differentiation of human marrow stromal cells cultured on ion-induced chemically structured poly-epsilon-caprolactone. *Biomaterials*, **2007**, 28, 1132-40 | 15.6 | 65 |
| 2 | Effects of activated platelet concentrates on human primary cultures of fibroblasts and osteoblasts. *Journal of Periodontology*, **2005**, 76, 323-8 | 4.6 | 45 |
| 1 | Increased osteoclast activity is associated with aggressiveness of osteosarcoma **1992**, 33, 1231 | | 15 |